Literature DB >> 16167149

[Malignant melanoma. Diagnosis and therapy].

E S Schultz1, G Schuler.   

Abstract

In Germany, 6100 women and 5300 men contract a malignant melanoma of the skin every year. The chances of being cured are good in the early stages of the disease, but the average survival following distant metastasis is only 6 to 9 months. Therefore, early diagnosis is crucial, particularly as the skin is, by nature, a readily accessible organ. The introduction of epiluminescence microscopy has increased diagnostic accuracy significantly. In cases of doubt, complete excision of the suspect pigmented lesion is always advisable. A light skin type, presence of numerous naevi, genetic predisposition (familial history) and increased UV exposure are considered as risk factors. As a rule, adjuvant imunotherapy with interferon-alphais recommended in high-risk patients. A multidisciplinary approach consisting of surgery, radiotherapy, chemotherapy and immunotherapy has proved beneficial in advanced stages of metastasis.

Entities:  

Mesh:

Year:  2005        PMID: 16167149     DOI: 10.1007/s00106-005-1326-y

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  79 in total

1.  Guidelines of care for primary cutaneous melanoma.

Authors:  A J Sober; T Y Chuang; M Duvic; E R Farmer; J M Grichnik; A C Halpern; V Ho; V Holloway; A F Hood; T M Johnson; B J Lowery
Journal:  J Am Acad Dermatol       Date:  2001-10       Impact factor: 11.527

2.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

Authors:  D Liénard; A M Eggermont; H S Koops; B Kroon; G Towse; S Hiemstra; P Schmitz; J Clarke; G Steinmann; F Rosenkaimer; F J Lejeune
Journal:  Melanoma Res       Date:  1999-10       Impact factor: 3.599

3.  [Malignant melanoma. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V].

Authors:  R Kaufmann; W Tilgen; C Garbe
Journal:  Hautarzt       Date:  1998-10       Impact factor: 0.751

4.  Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile?

Authors:  H S Koops; C Garbe; P Hohenberger
Journal:  Eur J Cancer       Date:  1996-09       Impact factor: 9.162

5.  Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.

Authors:  M J Paul; Y Summers; A H Calvert; G Rustin; M H Brampton; N Thatcher; M R Middleton
Journal:  Melanoma Res       Date:  2002-04       Impact factor: 3.599

6.  [Locally recurrent and metastatic malignant melanoma. Long-term results and prognostic factors after percutaneous radiotherapy].

Authors:  M H Seegenschmiedt; L Keilholz; A Pieritz; A Altendorf-Hofmann; A Urban; H Schell; W Hohenberger; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-09       Impact factor: 3.621

7.  Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.

Authors:  J J Costanzi; M Al-Sarraf; C Groppe; R Bottomley; C Fabian; J Neidhart; D Dixon
Journal:  Med Pediatr Oncol       Date:  1982

8.  Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group.

Authors:  U Ringborg; R Andersson; J Eldh; B Glaumann; L Hafström; S Jacobsson; P E Jönsson; H Johansson; L Krysander; B Lagerlöf
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

9.  A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma.

Authors:  S W Menzies; C Ingvar; W H McCarthy
Journal:  Melanoma Res       Date:  1996-02       Impact factor: 3.599

10.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

Authors:  M F Avril; S Aamdal; J J Grob; A Hauschild; P Mohr; J J Bonerandi; M Weichenthal; K Neuber; T Bieber; K Gilde; V Guillem Porta; J Fra; J Bonneterre; P Saïag; D Kamanabrou; H Pehamberger; J Sufliarsky; J L Gonzalez Larriba; A Scherrer; Y Menu
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  4 in total

1.  [Exophytic tumor of the neck].

Authors:  J Linke; M Neudert; A Forberger; T Zahnert
Journal:  HNO       Date:  2012-10       Impact factor: 1.284

2.  Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.

Authors:  Hua Zhong; Baohui Han; Irina L Tourkova; Anna Lokshin; Alan Rosenbloom; Michael R Shurin; Galina V Shurin
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

3.  A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.

Authors:  Michael Schwenkert; Katrin Birkholz; Michael Schwemmlein; Christian Kellner; Markus Kügler; Matthias Peipp; Dirk M Nettelbeck; Beatrice Schuler-Thurner; Niels Schaft; Jan Dörrie; Soldano Ferrone; Eckhart Kämpgen; Georg H Fey
Journal:  Melanoma Res       Date:  2008-04       Impact factor: 3.199

4.  Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA.

Authors:  K A Kessel; A Deichl; J Gempt; B Meyer; C Posch; C Diehl; C Zimmer; S E Combs
Journal:  Clin Transl Oncol       Date:  2021-05-15       Impact factor: 3.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.